Cellectis SA (CLLS)
2.99
0.00 (0.00%)
USD |
NASDAQ |
May 03, 16:00
3.05
+0.06
(+2.01%)
After-Hours: 20:00
Cellectis Cash from Investing (TTM): -15.51M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | -15.51M |
| September 30, 2023 | -2.021M |
| June 30, 2023 | -1.782M |
| March 31, 2023 | -1.549M |
| December 31, 2022 | -2.761M |
| September 30, 2022 | -2.802M |
| June 30, 2022 | -5.199M |
| March 31, 2022 | 5.99M |
| December 31, 2021 | 7.279M |
| September 30, 2021 | 4.745M |
| June 30, 2021 | 9.481M |
| March 31, 2021 | -5.483M |
| December 31, 2020 | -54.34M |
| September 30, 2020 | -54.14M |
| June 30, 2020 | -82.21M |
| March 31, 2020 | -79.97M |
| December 31, 2019 | -35.87M |
| Date | Value |
|---|---|
| September 30, 2019 | -35.40M |
| June 30, 2019 | 8.774M |
| March 31, 2019 | 31.71M |
| December 31, 2018 | 35.62M |
| September 30, 2018 | 37.17M |
| June 30, 2018 | 24.92M |
| March 31, 2018 | 4.053M |
| December 31, 2017 | 1.784M |
| September 30, 2017 | 49.76M |
| June 30, 2017 | 51.62M |
| March 31, 2017 | 49.40M |
| December 31, 2016 | -53.14M |
| September 30, 2016 | -101.50M |
| June 30, 2016 | -109.55M |
| March 31, 2016 | -109.90M |
| December 31, 2015 | -7.728M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-82.21M
Minimum
Jun 2020
9.481M
Maximum
Jun 2021
-18.04M
Average
-2.802M
Median
Sep 2022
Cash from Investing (TTM) Benchmarks
| Biophytis SA | 0.3879M |
| DBV Technologies SA | -0.808M |
| Genfit SA | -- |
| Edap TMS SA | -4.703M |
| Adaptimmune Therapeutics PLC | 176.54M |